

Press Release dated April 10, 2012

Contact: **Trinity Biotech plc**
Kevin Tansley
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com

Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700

Trinity Biotech plc to Announce First Quarter Fiscal Year 2012 Financial Results

**Conference Call Scheduled for April 19, 2012
at 11:00 am EASTERN**

DUBLIN – April 10, 2012 – Trinity Biotech plc (NasdaqGS: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter of fiscal year 2012 on Thursday, April 19, 2012. The Company has scheduled a conference call for that same day, Thursday, April 19, 2012 at 11:00am EDT (4:00pm BST) to discuss the results of the quarter.

Interested parties can access the call by dialing:

USA: 1-877-317-6789
International: 1-412-317-6789
Conference ID #: 10012694

A simultaneous webcast of the call can be accessed at:

<http://www.videonewswire.com/event.asp?id=86343>

A replay of the call can be accessed until April 25, 2012 by dialing:

USA: 1-877-344-7529
International: 1-412-317-0088
Conference ID #: 10012694

The webcast of the call will be available for 30 days at:

<http://www.videonewswire.com/event.asp?id=86343>

About Trinity Biotech plc

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website:

www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.